| Literature DB >> 35204215 |
Hamdoon A Mohammed1,2, Kamal A Qureshi3, Hussein M Ali4,5, Mohsen S Al-Omar1,6, Omar Khan7, Salman A A Mohammed4.
Abstract
Artemisia judaica (ArJ) is a Mediterranean aromatic plant used traditionally to treat gastrointestinal ailments, skin diseases, atherosclerosis, and as an immuno-stimulant. This study describes ArJ essential oil constituents and investigates their wound healing activity. The in vitro antioxidant and antibiofilm activities of ArJ essential oil were investigated. The in vivo pro/anti-inflammatory and oxidative/antioxidant markers were compared with standard silver sulfadiazine (SS) in a second-degree skin burn experimental rat model. The gas chromatography-equipped flame ionization detector (GC-FID) analysis of ArJ essential oil revealed the major classes of compounds as oxygenated monoterpenes (>57%) and cinnamic acid derivatives (18.03%). The antimicrobial tests of ArJ essential oil revealed that Bacillus cereus, Candida albicans, and Aspergillus niger were the most susceptible test organisms. Two second-degree burns (each 1 inch square in diameter) were created on the dorsum of rats using an aluminum cylinder heated to 120 °C for 10 s. The wounds were treated either with ArJ or SS ointments for 21 days, while the negative control remained untreated, and biopsies were obtained for histological and biochemical analysis. The ArJ group demonstrated a significant increase in antioxidant superoxide dismutase (SOD) and catalase (CAT) enzymatic activities, while lipid peroxide (LP) levels remained insignificant compared to the negative control group. Additionally, ArJ and SS groups demonstrated a significant decrease in inflammatory levels of tumor necrosis factor α (TNF-α) compared to the negative group, while interleukin 1 beta (IL-1b) and IL-6 were comparable to the negative group. At the same time, anti-inflammatory IL-10 and transforming growth factor beta 1 (TGF-b1) markers increased significantly in the ArJ group compared to the negative control. The ArJ results demonstrated potent wound healing effects, comparable to SS, attributable to antioxidant and anti-inflammatory effects as well as a high proportion of oxygenated monoterpenes and cinnamate derivatives.Entities:
Keywords: Artemisia judaica; antibiofilm activity; antioxidant activity; essential oil; inflammatory markers; wound healing
Year: 2022 PMID: 35204215 PMCID: PMC8868479 DOI: 10.3390/antiox11020332
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Major constituents of the ArJ essential oils from plant species growing in different areas.
| Locations | Major Constituents | Y% | Ref. |
|---|---|---|---|
| Saudi Arabia | cis-Thujone (2.5%), thymol (3.5%), trans-sabinyl acetate (3.3%), carvacrol (3.5%), b-eudesmol (13.1%), eudesma-4 (15), 7-dien-1-b-ol (3.5%), and hexadecanoic acid (5.7%) | 0.18% ( | [ |
| Algeria | Piperitone (66.17%), ethyl cinnamate isomer (6.11%), spathulenol (2.34%), E-longipinane (2.55%) | 1.7% ( | [ |
| Egypt | Piperitone (49.1%) and camphor (34.5%), borneol (3.90%) | [ | |
| Sinai, Egypt | Camphor (31.4%), endo-borneol (5.72%), piperitone (29.9%) | 0.28% | [ |
| Jordan | Artemisia ketone (9–24%), chrysanthenone (4–31%), piperitone (3–15%), camphor (0.3–16%), cinnamate (11.0%) | 0.4–0.9% ( | [ |
| Libya | cis-Chrysanthenol (9.1%), piperitone (30.2%), ethyl cinnamate (3.8%). | 0.62% ( | [ |
Y% refers to the yield of the essential oil.
Essential oil constituents of A. judaica growing in the Northern Qassim region of Saudi Arabia.
| RT | Chemical Compounds | Area Mean |
|
|
| Weight g/100 g of the Plant |
|---|---|---|---|---|---|---|
| 12.096 | (Z)-3-Hexenol | 0.50 ± 0.08 | 845 | 845 | 0.0085 | |
| 12.209 | 2-Methyl-ethylbutanoate | 0.4 ± 0.06 | 850 | 853 | 0.0068 | |
| 16.403 | Sabinene | 0.13 ± 0.11 | 953 | 954 | 59.04 (100%), 81.05 (96.37%), 96.07 (83.12%) | 0.0022 |
| 18.449 | α-Phellandrene | 1.30 ± 0.16 | 1000 | 999 | 68.04 (100%), 79.03 (42.69%), 93.04 (93.23%) | 0.0222 |
| 19.795 | Limonene | 0.72 ± 0.01 | 1029 | 1028 | 85.04 (100%), 55.03 (12.29%), 70.07 (7.28%) | 0.0123 |
| 20.239 | 1,8-Cineole | 2.56 ± 0.05 | 1038 | 1040 | 69.04 (100%), 110.08 (70.37%), 95.06 (46.98%) | 0.0437 |
| 21.359 | γ-Terpinene | 3.58 ± 0.18 | 1062 | 1063 | 135.05 (100%), 91.03 (20.36%), 107.03 (11.26%) | 0.0612 |
| 23.548 | Linalool | 1.21 ± 0.04 | 1108 | 1104 | 91.04 (100%), 92.04 (98.97%), 55.04 (47.04%) | 0.0207 |
| 23.739 | α-Thujone | 5.94 ± 0.09 | 1112 | 1112 | 95.06 (100%), 81.04 (68.49%), 109.04 (35.48%) | 0.1016 |
| 24.24 | β-Thujone | 3.61 ± 0.03 | 1123 | 1124 | 84.0 (100%), 55.02 (80.71%), 126.05 (47.17%) | 0.0617 |
| 24.49 | α-Campholenal | 0.91 ± 0.02 | 1128 | 82.04 (100%), 110.06 (91.66%), 95.04 (43.11%) | 0.0156 | |
| 24.639 | Terpinene-4-ol | 6.42 ± 0.17 | 1132 | 1140 | 70.04 (100%), 83.03 (71.89%), 71.03 (29.17) | 0.1098 |
| 25.443 | Isothujol | 0.27 ± 0.47 | 1149 | 1145 | 0.0046 | |
| 25.651 | Camphor | 1.92 ± 0.09 | 1154 | 1155 | 68.01 (100%), 81.02 (26.97%), 55.04 (18.33%) | 0.0328 |
| 26.454 | Borneol | 0.47 ± 0.01 | 1170 | 1170 | 95.04 (100%), 110.04 (48.36%), 54.06 (25.12%) | 0.0080 |
| 27.156 | p-Cymene-8-ol | 0.08 ± 0.14 | 1186 | 1185 | 135.06 (100%), 150.08 (40.42), 91.03 (32.05) | 0.0014 |
| 29.403 | Neral | 0.36 ± 0.00 | 1235 | 1236 | 69.02 (100%), 68.01 (17.21%), 83.01 (11.68%) | 0.0062 |
| 30.034 | Linalyl acetate | 0.10 ± 0.17 | 1249 | 1250 | 107.06 (100%), 95.04 (34.18), 55.03 (14.79%) | 0.0017 |
| 30.845 | Piperitone | 31.99 ± 0.50 | 1268 | 1260 | 82.04 (100%), 110.02 (37.44%), 95.06 (19.20%) | 0.5470 |
| 31.485 | Phellandral | 0.38 ± 0.02 | 1281 | 0.0065 | ||
| 31.965 | p-Cymen-7-ol | 0.08 ± 0.13 | 1292 | 1290 | 0.0014 | |
| 32.146 | Thymol | 1.81 ± 0.03 | 1296 | 1297 | 135.06 (100%), 107.03 (11.26), 77.01 (10.75%) | 0.0309 |
| 33.406 | Carvacrol | 0.10 ± 0.12 | 1325 | 1324 | 0.0017 | |
| 33.643 | Citronellyl acetate | 0.89 ± 0.02 | 1330 | 1334 | 107.06 (100%), 91.04 (39.11), 122.08 (15.51) | 0.0152 |
| 34.649 | ( | 0.35 ± 0.02 | 1354 | 1355 | 131.02 (100%), 103.03 (61.07), 162.04 (49.31%) | 0.0060 |
| 35.894 | 4.02 ± 0.06 | 1383 | 1376 | 131.04 (100%), 103.04 (48.29%), 77.03 (30.40%) | 0.0687 | |
| 36.303 | Jasmone | 0.71 ± 0.02 | 1392 | 1396 | 91.03 (100%), 95.03 (66.88%), 79.03 (60.65%) | 0.0121 |
| 36.658 | β-Bourbounene | 4.06 ± 0.17 | 1401 | 1401 | 111.02 (100%), 137.07 (41.99%), 180.09 (21.39%) | 0.0694 |
| 37.754 | β-Caryophyllene | 0.43 ± 0.08 | 1427 | 1429 | 161.12 (100%), 105.04 (57.31%), 93.05 (27.09%) | 0.0075 |
| 39.75 | 13.67 ± 0.55 | 1477 | 1455 | 131.04 (100%), 103.04 (48.29%), 77.03 (30.40%) | 0.2337 | |
| 40.542 | Valencene | 3.24 ± 0.09 | 1497 | 1497 | 161.12 (100%), 105.04 (57.31%), 91.04 (53.35%) | 0.0554 |
| 41.138 | 0.79 ± 0.14 | 1511 | 1513 | 161.11 (100%), 133.07 (30.58%), 120.07 (27.73%) | 0.0135 | |
| 41.968 | σ-Cadinene | 2.37 ± 0.09 | 1532 | 1526 | 91.04 (100%), 205.11 (86.11%), 77.02 (46.25%) | 0.04052476 |
| 44.321 | Spathulenol | 3.33 ± 0.07 | 1593 | 1575 | 91.04 (100%), 93.05 (73.39), 77.02 (46.25%) | 0.0569 |
| 47.198 | β-Eudesmol | 0.22 ± 0.19 | 1671 | 1672 | 59.04 (100%), 149.11 (67.04%), 146.14 (33.10%) | 0.0038 |
| 48.344 | a-Caryophylene acetate | 1.11 ± 0.31 | 1702 | 1696 | 67.04 (100%), 95.06 (62.38%), 96.07 (41.92%) | 0.0190 |
| Total | 100 | 1.71 | ||||
| Monoterpene hydrocarbons | 5.74 | |||||
| Oxygenated monoterpenes | 57.20 | |||||
| Sesquiterpene hydrocarbons | 10.88 | |||||
| Oxygenated sesquiterpenes | 4.66 | |||||
| Phenolics | 1.87 | |||||
| Cinnamic acid derivatives | 18.03 | |||||
RT, Retention time; RI, Calculated retention index; RI, Reported retention index; m/z, mass to charge ratio.
Figure 1Representation of the oxygenated monoterpenes in A. judaica essential oil.
Figure 2Preliminary antimicrobial activity of ArJ essential oil. (a) Staphylococcus aureus (S. aureus) ATCC 29213; (b) Staphylococcus saptophyticus (S. saptophyticus) ATCC 43867; (c) Streptococcus pyogenes (S. pyogenes)-A ATCC 27736; (d) Streptococcus pneumoniae (S. pneumoniae) ATCC 49619; (e) Enterococcus faecalis (E. faecalis) ATCC 29212; (f) Bacillus cereus (B. cereus) ATCC 10876; (g) Escherichia coli (E. coli) ATCC 25922; (h) Klebsiella pneumonie (K. pneumoniae) ATCC 27736; (i) Salmonella typhimurium (S. typhimurium) ATCC 13311; (j) Shigella flexneri (S. flexneri) ATCC 12022; (k) Proteus vulgaris (P. vulgaris) ATCC 6380; (l) Proteus mirabilis (P. mirabilis) ATCC 29906; (m) Candida albicans (C. albicans) ATCC 10231; (n) Aspergillus niger (A. niger) ATCC 6275. AJ referred to Artemisia judaica essential oil, while C referred to the drug control.
Preliminary antimicrobial activity of ArJ essential oil.
| Microorganisms | Zone of Inhibition (mm) | |
|---|---|---|
| ArJ Essential Oil | Control Drugs | |
| 7.7 ± 0.20 | 14.2 ± 0.20 | |
| 8.8 ± 0.20 | 12.8 ± 0.20 | |
| 7.4 ± 0.30 | 11.7 ± 0.10 | |
| 7.2 ± 0.17 | 11.7 ± 0.20 | |
| 8.7 ± 0.17 | 11.9 ± 0.10 | |
| 12.9 ± 0.10 | 19.6 ± 0.35 | |
| 6.4 ± 0.10 | 23.1 ± 0.20 | |
| 6.2 ± 0.10 | 21.1 ± 0.10 | |
| 10.0 ± 0.20 | 16.3 ± 0.30 | |
| 6.2 ± 0.10 | 17.9 ± 0.17 | |
| 8.1 ± 0.17 | 16.2 ± 0.35 | |
| 7.7 ± 0.20 | 18.7 ± 0.20 | |
| 25.2 ± 0.20 | 25.0 ± 0.20 | |
| 15.0 ± 0.20 | 13.1 ± 0.35 | |
Note: All results are in mean ± SD. Each test was performed in triplicate. Control drugs = levofloxacin (antibacterial), 5 µg/disc; and clotrimazole (antifungal), 50 µg/disc.
Results of MIC, MBC, MBIC, and MBEC of ArJ essential oil.
| Microorganisms | MIC | MBC | MBIC | MBEC |
|---|---|---|---|---|
| 50 | 100 | 50 | 100 | |
| 50 | 100 | 50 | 100 | |
| 100 | >100 | 100 | 200 | |
| 100 | >100 | 100 | 200 | |
| 100 | >100 | 100 | 200 | |
| 6.25 | 12.5 | 6.25 | 12.5 | |
| 50 | 100 | 50 | 100 | |
| 25 | 50 | 25 | 50 | |
| 12.5 | 25 | 12.5 | 25 | |
| 12.5 | 25 | 12.5 | 25 | |
| 25 | 50 | 25 | 50 | |
| 100 | >100 | 100 | 200 | |
| 6.25 | 12.5 | NT | NT | |
| 3.125 | 6.25 | NT | NT |
Note: All the results are in µL/mL. NT = Not tested. MIC = Minimum Inhibitory Concentration, MBC = Minimum Biocidal Concentration, MBIC = Minimum Biofilm Inhibitory Concentration, MBEC = Minimum Biofilm Eradication Concentration. All the results are in µL/mL.
Figure 3Morphological appearances of Artemisia judaica (G1)- and silver sulfadiazine (SS) (G2)-treated wounds at various time points.
Figure 4Histological analysis using hematoxylin and eosin staining of control (A), Artemisia judaica (B), and SS (C). Arrows (black) indicate neutrophil infiltration; magnification 40×.
Effect of Artemisia judaica ointment on antioxidant and oxidant levels in skin burn rat model.
| Groups | CAT | SOD | LP |
|---|---|---|---|
| ng/g | |||
| I. Intact control | 1.35 ± 0.05 A,B | 0.04 ± 0.00 A | 836.9 ± 37.75 A |
| II. Negative control (skin burn without treatment) | 1.11 ± 0.06 A | 0.04 ± 0.01 A | 1214 ± 51.46 B |
| III. Silver sulfadiazine | 1.79 ± 0.204 B | 0.19 ± 0.06 A,B | 1197 ± 30.30 B |
| IV. | 1.82 ± 0.17 B | 0.37 ± 0.13 B | 1291 ± 18.85 B |
Values are denoted as means ± SEM (Supplementary file, Tables S1–S3). Statistical significance was performed using one-way ANOVA, followed by a post hoc test on GraphPad Prism 8.0.2. CAT = catalase, LP = lipid peroxide, SOD = Superoxide dismutase. The mean values that do not share a superscript letter (A,B) in the respective columns of superoxide dismutase (SOD), catalase (CAT), and lipid peroxide (LP) are significantly different (p < 0.05) using Tukey’s multi-group comparisons.
Effect of Artemisia judaica ointment on inflammatory and pro-angiogenic markers in skin burn rat model.
| Groups | IL-1b | IL-6 | TNF-α | TGF-b1 | IL-10 |
|---|---|---|---|---|---|
| ng/g | |||||
| I. Intact control | 20.77 ±1.95 A | 806.1 ±10.20 A | 9.57 ±0.55 A | 4.19 ±0.24 A | 3.54 ±0.19 A |
| II. Negative control (skin burn without treatment) | 19.37 ± 2.33 A | 776.2 ±32.77 A | 15.54 ± 0.92 B | 3.87 ± 0.09 A | 2.99 ± 0.25 A |
| III. Sulfadiazine | 23.55± 0.88 A | 789.4 ±18.02 A | 12.85± 0.26 C | 19.28± 0.30 B | 12.68± 0.15 B |
| IV. | 19.55 ± 1.34 A | 869.2 ±51.91 A | 11.96 ± 0.34 C | 19.18 ± 0.33 B | 13.39 ± 0.35 B |
Values are denoted as means ± SEM (Supplementary file, Tables S4–S8). Statistical significance was performed using one-way ANOVA, followed by a post hoc test on GraphPad Prism 8.0.2. The mean values that do not share a superscript letter (A–C) in the respective columns of interleukin-1 (IL-1b), IL-6, IL-10, transforming growth factor beta 1 (TGF-b1), and tumor necrosis factor α (TNF-α) are significantly different (p < 0.05) using Tukey’s multi-group comparisons.